Human studies, approvals, and regulatory pathways.
Phase I, n=30 – Blocks USAG-1 protein to activate dormant tooth buds. Successful in mice, ferrets, dogs. Caveats: Currently only for congenital tooth loss (born without teeth), not cavities/injury. General availability target: 2030 (if trials succeed).